🚀 VC round data is live in beta, check it out!
Svas Biosana Valuation Multiples
Discover revenue and EBITDA valuation multiples for Svas Biosana and similar public comparables like AOTI, Anatolia Geneworks, SMAIO, Tobii and more.
Svas Biosana Overview
About Svas Biosana
Svas Biosana SpA operates in the production and distribution of medical device.
Founded
1972
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$124M
Svas Biosana Financials
Svas Biosana reported last 12-month revenue of $168M and EBITDA of $22M.
In the same LTM period, Svas Biosana generated $22M in EBITDA and $9M in net income.
Revenue (LTM)
Svas Biosana P&L
In the most recent fiscal year, Svas Biosana reported revenue of $144M and EBITDA of $21M.
Svas Biosana expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $168M | XXX | $144M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $57M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $22M | XXX | $21M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $9M | XXX | $7M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $39M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Svas Biosana Stock Performance
Svas Biosana has current market cap of $55M, and enterprise value of $124M.
Market Cap Evolution
Svas Biosana's stock price is $10.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $124M | $55M | 0.0% | XXX | XXX | XXX | $1.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSvas Biosana Valuation Multiples
Svas Biosana trades at 0.7x EV/Revenue multiple, and 5.6x EV/EBITDA.
EV / Revenue (LTM)
Svas Biosana Financial Valuation Multiples
As of April 20, 2026, Svas Biosana has market cap of $55M and EV of $124M.
Equity research analysts estimate Svas Biosana's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Svas Biosana has a P/E ratio of 6.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV (current) | $124M | XXX | $124M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 5.6x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBIT | 8.4x | XXX | 10.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.2x | XXX | XXX | XXX |
| P/E | 6.5x | XXX | 8.0x | XXX | XXX | XXX |
| EV/FCF | 27.9x | XXX | (106.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Svas Biosana Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Svas Biosana Margins & Growth Rates
Svas Biosana's revenue in the last 12 month grew by 7%.
Svas Biosana's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Svas Biosana's rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Svas Biosana Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Svas Biosana Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Svas Biosana | XXX | XXX | XXX | XXX | XXX | XXX |
| AOTI | XXX | XXX | XXX | XXX | XXX | XXX |
| Anatolia Geneworks | XXX | XXX | XXX | XXX | XXX | XXX |
| SMAIO | XXX | XXX | XXX | XXX | XXX | XXX |
| Tobii | XXX | XXX | XXX | XXX | XXX | XXX |
| Envoy Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Svas Biosana M&A Activity
Svas Biosana acquired XXX companies to date.
Last acquisition by Svas Biosana was on XXXXXXXX, XXXXX. Svas Biosana acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Svas Biosana
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSvas Biosana Investment Activity
Svas Biosana invested in XXX companies to date.
Svas Biosana made its latest investment on XXXXXXXX, XXXXX. Svas Biosana invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Svas Biosana
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Svas Biosana
| When was Svas Biosana founded? | Svas Biosana was founded in 1972. |
| Where is Svas Biosana headquartered? | Svas Biosana is headquartered in Italy. |
| Is Svas Biosana publicly listed? | Yes, Svas Biosana is a public company listed on Borsa Italiana. |
| What is the stock symbol of Svas Biosana? | Svas Biosana trades under SVS ticker. |
| When did Svas Biosana go public? | Svas Biosana went public in 2021. |
| Who are competitors of Svas Biosana? | Svas Biosana main competitors are AOTI, Anatolia Geneworks, SMAIO, Tobii. |
| What is the current market cap of Svas Biosana? | Svas Biosana's current market cap is $55M. |
| What is the current revenue of Svas Biosana? | Svas Biosana's last 12 months revenue is $168M. |
| What is the current revenue growth of Svas Biosana? | Svas Biosana revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Svas Biosana? | Current revenue multiple of Svas Biosana is 0.7x. |
| Is Svas Biosana profitable? | Yes, Svas Biosana is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Svas Biosana? | Svas Biosana's last 12 months EBITDA is $22M. |
| What is Svas Biosana's EBITDA margin? | Svas Biosana's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Svas Biosana? | Current EBITDA multiple of Svas Biosana is 5.6x. |
| What is the current FCF of Svas Biosana? | Svas Biosana's last 12 months FCF is $4M. |
| What is Svas Biosana's FCF margin? | Svas Biosana's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Svas Biosana? | Current FCF multiple of Svas Biosana is 27.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.